Advertisement

Topics

FDA Approves Astellas’ Xospata for Adults with Relapsed/Refractory Acute Myeloid Leukemia with a FLT3 Mutation

11:20 EST 29 Nov 2018 | Speciality Pharma Journal

TOKYO, Nov. 28, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) approved XOSPATA® (generic name: gilteritinib) for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation …

Original Article: FDA Approves Astellas’ Xospata for Adults with Relapsed/Refractory Acute Myeloid Leukemia with a FLT3 Mutation

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Astellas’ Xospata for Adults with Relapsed/Refractory Acute Myeloid Leukemia with a FLT3 Mutation"

Advertisement
Quick Search
Advertisement
Advertisement